# Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

> **NCT00071058** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Adrenal Cortex Neoplasms

## Interventions

- **DRUG:** XR9576 (Tariquidar)

## Key facts

- **NCT ID:** NCT00071058
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00071058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00071058, "Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00071058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*